TIANFU-CHEM 497-76-7 Arbutin CAS NO.497-76-7

Min.Order Quantity:: 1 Kilogram

Purity:: 99.5%

Port:: China main port

Payment Terms:: L/C,T/T

Add to Inquiry Cart

Product Details

Keywords

497-76-7
?-Arbutin
497-76-7

Quick Details

ProName: TIANFU-CHEM 497-76-7 Arbutin
CasNo: 497-76-7
Molecular Formula: C12H16O7
Appearance: White needle crystal or powder
Application: White needle crystal or powder
DeliveryTime: within 20 days
PackAge: 25kg/pp bag
Port: China main port
ProductionCapacity: 5 Metric Ton/Day
Purity: 99.5%
Storage: Placed in the dark, a cool, dry place ...
Transportation: by air or sea
LimitNum: 1 Kilogram

Superiority

our company was built in 2009 with an iso certificate.in the past 5 years, we have grown up as a famous fine chemicals supplier in china and we had established stable business relationships with samsung,lg,merck,thermo fisher scientific and so on.our main business covers the fields below:

1.noble metal catalysts (pt.pd...)

2.organic phosphine ligands (tert-butyl-phosphine.cyclohexyl-phosphine...)

3.oled intermediates (fluorene,carbazole,boric acid...)

4.customs synthesis

our advantage:

1. higest quality and good package

2.fast delivery

3.better payment term

4.fast response to customer within 6 hours

5.good business credit in europe ,us ,japan ,korea

anyway ,if you need any chemicals from china ,henan tianfu can help you

Details

dutasteride basic information

medicines to treat benign prostatic hyperplasia clinical evaluation application

product name:	dutasteride
synonyms:	(5alpha,17beta)-n-{2,5-bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-l-ene-17-carboxamide;dutasteride;gg-745, gi-198745,;5α,17β)-n-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4- aza -androst-1-ene-17-carboxamide;duagen;(5a,17)-n-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-azaandrost-1-ene-17-carboxamide;avodart;gi 198745
cas:	164656-23-9
mf:	c27h30f6n2o2
mw:	528.53
einecs:
product categories:	miscellaneous biochemicals;all inhibitors;inhibitors;intermediates & fine chemicals;pharmaceuticals;steroids;steroid and hormone;hormone drugs;api
mol file:	164656-23-9.mol

dutasteride chemical properties

mp	242-250°c
storage temp.	-20°c freezer

safety information

msds information

dutasteride usage and synthesis

medicines to treat benign prostatic hyperplasia	on october 9, 2002, dutasteride that was developed by gsk was approved by the us food and drug administration for the use in the treatment of prostate enlargement. on june 19, 2008, gsk announced that the fda approved for the combination of idutasteride and tamsulosin in the treatment of prostate hyperplasia. in china, on of two elderly men over the age of 60 have benign prostatic hyperplasia. it can cause urinary tract symptoms, including significant rise in frequency of urination, thin urine flow, bladder emptying difficulties, as well as nocturia. it even can cause serious complications, like acute urinary retention, reduce the patients’ life quality, and affect their social life. dutasteride is the first and the only dual 5α reductase inhibitor to be used in the treatment of prostatic hyperplasia. it can improve urinary system symptom, reduce the onset of acute urinary retention and the risk of prostate surgery. tamsulosin is α receptor blockers. it can improve the symptom of prostate hyperplasia. the human body has both type i reductase and type ii 5α reductase. type ii mainly exists in the prostate. and type i mainly distributes in the liver and skin. 5α reductase is the important reason that leads benign hyperplastic prostate disease continuous developing. it can make testosterone in patients’ prostate transform to dht with stronger activity, which can cause prostate cells hyperplasia and prostate hypertrophy. therefore, the inhibition of 5α reductase is the key to treat benign prostatic hyperplasia. and dutasteride can inhibit the type i and type ii 5α reductase at the same time. through this double inhibition mechanism, dutasteride can rapidly and continuously decrease prostate volume, significantly improve the urinary symptoms, reduce the risk of acute urinary retention and related prostate surgery, and bring benefit to patients with persistent, especially the middle and severe patients with benign prostatic hyperplasia. the above information is edited by the chemicalbook geqian.
clinical evaluation	the approval of the us food and drug administration bases on a multicenter randomized double-blind controlled clinical study for two years -- the first long-term evaluation of the combination of dutasteride and alpha blockers in clinical research. the patients include moderate and severe prostate hyperplasia patients (age is greater than or equal to 50, prostatic volume (pv) ≥ 30cc, serum prostate specific antigen (psa) level is 1.5 ~ 10 ng/ml, 5 ml/s < maximum urinary flow rate (qmax) ≤15 ml/s, the minimum urine output ≥ 125 ml, the international prostate symptom score (ipss) ≥ 12). patients firstly take placebo for four weeks, and then randomly take both dutasteride 0.5 mg/day and tamsulosin 0.4 mg/day, or only take dutasteride 0.5 mg/day, tamsulosin 0.4 mg/day. the clinical study shows that the treatment effect of the combination of dutasteride is better than single treatment after twelve and twenty-four months. the most common adverse reactions of this product are impotence, decreased libido, breast disease (including breast augmentation, swelling), ejaculatory dysfunction, and dizziness.
application	dutasteride is 5α reductase inhibitor.
chemical properties	white crystalline solid
usage	used in the treatment of benign prostatic hyperplasia. dual inhibitor of 5a-reductase isoenzymes type 1 and 2; structurally related to finasteride.
usage	used in the treatment of benign prostatic hyperplasia. dual inhibitor of 5α-reductase isoenzymes type 1 and 2; structurally related to finasteride.
usage	antihypertensive, ace inhiibitor
usage	dutasteride is a dual inhibitor of 5α-reductase isoenzymes type 1 and 2; structurally related to finasteride (f342000). dutasteride is used in the treatment of benign prostatic hyperplasia.